期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 25, 期 4, 页码 473-482出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2014.07.009
关键词
Anti-angiogenic therapy; Anti-angiogenic therapy resistance; Tumor microenvironment; Cancer; Vascular endothelial growth factor
资金
- Belgian Science Policy Federal Government [IUAP P7/03]
- Flemish Government
- FWO [G.0817.11, 0834.13, 0658.14]
- Foundation Leducq Transatlantic Network (ARTEMIS)
- Foundation against cancer [2012-175]
- European Research Council (ERC) Advanced Research Grant [EU-ERC269073]
- AXA Research Fund [1465]
Vascular endothelial growth factor (VEGF) is a key growth factor driving angiogenesis (i.e. the formation of new blood vessels) in health and disease. Pharmacological blockade of VEGF signaling to inhibit tumor angiogenesis is clinically approved but the survival benefit is limited as patients invariably acquire resistance. This is partially mediated by the intrinsic flexibility of tumor cells to adapt to VEGF-blockade. However, it has become clear that tumor stromal cells also contribute to the resistance. Originally, VEGF was thought to specifically target endothelial cells (ECs) but it is now clear that many stromal cells also respond to VEGF signaling, making anti-VEGF therapy more complex than initially anticipated. A more comprehensive understanding of the complex responses of stromal cells to VEGF-blockade might inform the design of improved anti-angiogenic agents. (C) 2014 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据